Table 1.
Clinical features of tumors, immunohistochemistry of tru-cut core biopsies before chemotherapy, and reverse-transcriptase-mediated polymerase chain reaction (RT-PCR) after chemotherapy
| Number of | c494 | MDR1 | ||||||||||
| Histology | Size | invaded nodes | erb | p53 | Ki67 (%) | ER | PR | MDR1 | LRP | Chemotherapy | Response | (RT-PCR) |
| Lobular | 8.0 | 32 | 0 | 0 | 30 | 0 | 0 | FAC4 | SD | 0 | ||
| Ductal | 7.0 | 31 | 1 | 1 | 60 | 0 | 0 | Ttere-ADM4 | PR | 1 | ||
| Ductal | 6.0 | 21 | 1 | 1 | 30 | 1 | 1 | 1 | FAC4 | PR | 1 | |
| Ductal | 3.5 (T4b) | 20 | 1 | 0 | 5 | 0 | 0 | 0 | 1 | FAC3 | PR | 1 |
| Ductal | 6.0 | 20 | 0 | 0 | 35 | 0 | 0 | 1 | 1 | FAC4 | SD | 1 |
| Lobular | 7.0 | 18 | 0 | 0 | 20 | 1 | 1 | FAC4 | PR | 0 | ||
| Ductal | 3 (T4b) | 16 | 0 | 0 | 30 | 1 | 1 | 0 | 1 | FAC4 | PR | 1 |
| Ductal | Diffuse | 15 | 0 | 0 | 20 | 0 | 0 | FAC4 | PR | 0 | ||
| Lobular | Diffuse | 11 | 0 | 0 | 80 | 1 | 1 | 1 | 1 | FAC6 | PR | 1 |
| Ductal | 2.2 (T4b) | 10 | 0 | 1 | 30 | 0 | 0 | 0 | 1 | FAC4 | PR | 0 |
| Ductal | 7.0 | 10 | 0 | 0 | 35 | 1 | 0 | 1 | 1 | FAC4 | PR | 1 |
| Ductal | 3 (T4b) | 10 | 1 | 1 | 20 | 1 | 1 | FAC4 | PR | Failed | ||
| Ductal | 5.0 | 9 | 1 | 0 | 20 | 0 | 0 | FAC4 | SD | Failed | ||
| Ductal | 2.2+1.3 | 9 | 1 | 0 | 50 | 1 | 1 | 0 | 1 | FAC4 | PR | 1 |
| Ductal | 4.0 (T4b) | 8 | 1 | 1 | 1 | 1 | FAC4 | PR | 0 | |||
| Lobular | 3.0 | 8 | 0 | 0 | 2 | 1 | 1 | 0 | FAC4 | SD | 0 | |
| Ductal | Diffuse | 7 | 1 | 0 | 20 | 1 | 0 | 1 | FAC4 | SD | 1 | |
| Ductal | 8.0 | 7 | 1 | 1 | 50 | 0 | 0 | 1 | 1 | FAC4 | CCR | 1 |
| Ductal | 5.0 (T4b) | 5 | 0 | 0 | 5 | 0 | 0 | FAC3 | PR | 0 | ||
| Ductal | Diffuse | 4 | 0 | 0 | 50 | 1 | 0 | 1 | FAC4 | PR | 1 | |
| Ductal | 10.0 | 3 | 0 | 0 | 80 | 0 | 0 | 1 | FAC3 | PR | Failed | |
| Ductal | 6.0 | 3 | 1 | 0 | 40 | 0 | 0 | 1 | FAC4 | SD | 0 | |
| Ductal | 4.5 (T4b) | 2 | 0 | 0 | 30 | 1 | 1 | FAC6 | SD | 1 | ||
| Ductal | 2.5 | 2 | 0 | 0 | no | 0 | 0 | FAC4 | PR | Failed | ||
| Ductal | 10.0 | 2 | 0 | 1 | 60 | 0 | 0 | FAC4 | CCR | 1 | ||
| Ductal | 4.5+2.0 | 2 | 0 | 0 | 25 | 1 | 1 | 0 | 0 | CMF4 | PR | 0 |
| Ductal | 5.0 | 2 | 1 | 1 | 40 | 1 | 0 | 0 | FAC4 | PR | 0 | |
| Ductal | 3.5 | 2 | 0 | 0 | 15 | 1 | 1 | 0 | 1 | FAC4 | SD | 0 |
| Ductal | 3.0 | 2 | 0 | 1 | 35 | 0 | 0 | 1 | FAC4 | SD | 0 | |
| Ductal | 2.0 | 2 | 0 | 0 | 30 | 1 | 0 | 1 | FAC4 | PR | 1 | |
| Ductal | 2.6+2.3 | 1 | 0 | 0 | 40 | 1 | 1 | FAC3 | PR | 1 | ||
| Ductal | 3.5 | 1 | 0 | 0 | 15 | 1 | 1 | 1 | 1 | FAC4 | PR | 1 |
| Undiff. | 6.0 | 1 | 0 | 1 | 45 | 0 | 0 | FAC6 | SD | 1 | ||
| Lobular | 6.0 | 1 | 0 | 0 | 10 | 1 | 1 | 0 | 0 | FAC4 | PR | 0 |
| Ductal | 3.0 | 1 | 0 | 1 | 70 | 0 | 0 | 1 | 1 | FAC2 | PR | 1 |
| Ductal | 5+2 | 0 | 1 | 1 | 20 | 0 | 1 | FAC3 | PR | Failed | ||
| Ductal | 3.5 | 0 | 1 | 0 | 12 | 0 | 0 | 0 | 0 | FAC3 | PR | 0 |
| Ductal | 10.0 | 0 | 0 | 1 | 15 | 0 | 0 | FAC5 | SD | 0 | ||
| Ductal | 6.0 | 0 | 0 | 1 | 15 | 1 | 1 | FAC4 | PR | 1 | ||
| Lobular | 5.0 | 0 | 0 | 0 | 10 | 1 | 1 | 1 | 0 | FAC4 | PR | 0 |
| Ductal | 5.0 | 0 | 0 | 0 | 10 | 1 | 1 | FAC4 | PR | 0 | ||
| Ductal | 4.0 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 0 | FAC4 | PR | 0 |
| Ductal | 5.0 | 0 | 0 | 0 | 10 | 1 | 1 | 0 | 1 | FAC4 | PR | ND |
| Ductal | 6.0 | 0 | 1 | 1 | 25 | 1 | 1 | FAC4 | PR | 1 | ||
| Ductal | 2.0 (T4a) | 0 | 1 | 1 | 30 | 1 | 1 | FAC4 | SD | 0 | ||
| Ductal | 5.0 | 0 | 0 | 0 | 25 | 1 | 0 | 0 | 0 | FAC4 | PR | 0 |
| Ductal | 5.0 | 0 | 0 | 0 | 15 | 1 | 1 | 0 | 0 | FAC4 | PR | 0 |
| Ductal | 6.0 | 0 | 0 | 1 | 80 | 0 | 0 | 0 | 1 | FAC4 | PR | 1 |
| Ductal | 3.6 | 0 | 0 | 0 | 10 | 1 | 1 | 1 | 1 | FAC4 | SD | 0 |
| Ductal | 3.5 | 0 | 0 | 1 | 15 | 0 | 0 | 1 | FAC4 | PR | 1 | |
| Ductal | 4.0 | 0 | 0 | 0 | 20 | 1 | 0 | 1 | FAC4 | PR | 0 | |
| Ductal | 5.0 | 0 | 0 | 0 | 10 | 1 | 1 | 1 | FAC4 | PR | 0 |
Responses: 1, positive, 0, negative. Positivity levels: MDR1 (c494), only membrane staining in more than 10% of tumor cells; LRP, more than 20% reactive cells (for details, see the text). CCR, complete clinical response; PR, partial response; SD, stable disease; F, 5-fluorouracyl; A, doxorubicin (adriamycin); C, cyclophosphamide; M, methotrexate; undiff, undifferentiated; ND, not done; Ttere, taxotere.